In the case of using PSA level in combination with systematic biopsies, this approach necessitated more biopsies but resulted in a lower detection rate of clinically significant prostate cancer compared with either the Stockholm3 risk score or the MRI-enhanced approach (Table 2). This evidence concerns the gene KLK3 and prostate carcinoma.